-
公开(公告)号：US20250067750A1
公开(公告)日：2025-02-27
申请号：US18787598
申请日：2024-07-29
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Abu Nahiyaan Navid , Yunlong Zhao , Yuan Mao , Ning Li
Abstract: The present invention generally pertains to methods of characterizing non-consensus glycosylation sites of a protein. In particular, the present invention pertains to the use of high-throughput automated processes through digestion, enrichment of glycopeptides by liquid chromatography-mass spectrometry for identifying identification of non-consensus glycosylation sites.
-
公开(公告)号：US20250051466A1
公开(公告)日：2025-02-13
申请号：US18429887
申请日：2024-02-01
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Israel Lowy , David Sternberg , Manish Sharma , Lieve Adriaens
Abstract: B-cell maturation antigen (BCMA) is expressed on malignant plasma cells. The present invention provides methods for treating multiple myeloma using bispecific antibodies (bsAbs) that bind to both BCMA and CD3 and activate T cells via the CD3 complex in the presence of BCMA-expressing tumor cells. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing BCMA.
-
公开(公告)号：US12221619B2
公开(公告)日：2025-02-11
申请号：US18371959
申请日：2023-09-22
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Amy S. Johnson , Meghan E. Casey , Shadia Oshodi , Shawn Lawrence
Abstract: The specification describes a composition comprising an improved eukaryotic cell culture medium, which can be used for the production of a protein of interest. TaXULne can be added to the serum-free media or chemically-defined media to increase the production of a protein of interest. Methods for recombinantly expressing high levels of protein using the media compositions are included.
-
公开(公告)号：US20250043017A1
公开(公告)日：2025-02-06
申请号：US18766802
申请日：2024-07-09
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Saida Dadi-Mehmetaj , Lauric Haber , Jessica Kirshner , Lauren Canova-Kleinman , Erica Ullman
Abstract: The present disclosure provides bispecific antigen-binding molecules that bind to PD-L1 and 4-1BB (PD-L1×4-1BB). In certain embodiments, the present disclosure provides a bispecific PD-L1×4-1BB antibody or antigen-binding fragment thereof comprising a first antigen-binding domain that specifically binds 4-1BB, and a second antigen-binding domain that specifically binds PD-L1. In certain embodiments, the bispecific antibodies disclosed herein bind 4-1BB on T-cells with the first antigen-binding domain and PD-L1 expressed on tumor cells or antigen presenting cells with the second antigen-binding domain. In certain embodiments, the antibodies of the present disclosure are useful in treatment of a cancer.
-
公开(公告)号：US20250043002A1
公开(公告)日：2025-02-06
申请号：US18766785
申请日：2024-07-09
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Saida Dadi-Mehmetaj , Lauric Haber , Jessica Kirshner , Lauren Canova-Kleinman , Erica Ullman
Abstract: The present disclosure provides bispecific antigen-binding molecules that bind to PD-L1 and CD28 (PD-L1×CD28). In certain embodiments, the present disclosure provides for a bispecific PD-L1×CD28 antigen-binding molecule (or antibody) or antigen-binding fragment thereof comprising a first antigen-binding domain that specifically binds CD28, and a second antigen-binding domain that specifically binds PD-L1. In certain embodiments, the bispecific antigen-binding molecules of the present disclosure bind CD28 on T-cells with the first antigen-binding domain and PD-L1 expressed on tumor cells or antigen presenting cells with the second antigen-binding domain. In certain embodiments, the bispecific antigen-binding molecules are capable of inhibiting growth of a tumor. The bispecific antigen-binding molecules of this disclosure are useful for treatment of cancer.
-
公开(公告)号：US20250040522A1
公开(公告)日：2025-02-06
申请号：US18717225
申请日：2022-12-08
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Gaurang Patel , Charleen Hunt , Yajun Tang , Qing Fang , Guochun Gong , Ying Hu , Carmelo Romano
IPC: A01K67/0275 , C07K14/005 , C07K14/47 , C12N9/22 , C12N15/113 , C12N15/86
Abstract: Non-human animal genomes, non-human animal cells, and non-human animals comprising a humanized MYOC locus and methods of making and using such non-human animal genomes, non-human animal cells, and non-human animals are provided. Non-human animal cells or non-human animals comprising a humanized MYOC locus express a human myocilin protein or a chimeric myocilin protein, fragments of which are from human myocilin. Methods are provided for using such non-human animals comprising a humanized MYOC locus to assess in vivo efficacy of human-myocilin-targeting reagents and reagents for treating glaucoma.
-
公开(公告)号：US20250026828A1
公开(公告)日：2025-01-23
申请号：US18756267
申请日：2024-06-27
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Kevin Friedman , Molly Reed Perkins
IPC: C07K16/28 , A61K39/00 , C07K14/705 , C12N5/0783 , C12N15/86
Abstract: The invention provides improved compositions for adoptive cell therapies for cancers that express CD79A.
-
公开(公告)号：US20250025531A1
公开(公告)日：2025-01-23
申请号：US18751087
申请日：2024-06-21
Applicant: Regeneron Pharmaceuticals, Inc. , Bayer HealthCare LLC
Inventor： Robert L. Vitti , Alyson J. Berliner , Karen W. Chu , Friedrich Asmus , Sergio Casimiro da Silva Leal , Thomas Eißing , Kay D. Rittenhouse
Abstract: The present invention relates to regimens for the treatment of angiogenic eye disorders such as nAMD, DR and DME characterized by high doses of aflibercept extended periods between doses.
-
公开(公告)号：US12187792B2
公开(公告)日：2025-01-07
申请号：US16805481
申请日：2020-02-28
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Caroline Liot , Frank Kuhnert
Abstract: The disclosure relates to methods for treating or inhibiting the growth of a tumor, wherein the methods include selecting and administering to a subject in need thereof a therapeutically effective amount of an IL-4/IL-13 pathway inhibitor and a therapeutically effective amount of a programmed death 1 (PD-1) inhibitor. In certain embodiments, the IL-4/IL-13 pathway inhibitor enhances the anti-tumor efficacy of PD-1 blockade.
-
公开(公告)号：US20250000949A1
公开(公告)日：2025-01-02
申请号：US18804421
申请日：2024-08-14
Applicant: Regeneron Pharmaceuticals, Inc.
Inventor： Yang Wei , Haruka Okamoto , Jesper Gromada , Samuel Davis , Andrew J. Murphy
IPC: A61K38/26 , A61K31/155 , A61K31/5415 , A61K38/00 , A61P3/04 , A61P3/10 , C07K14/605 , C07K16/08 , C07K16/28 , C12N15/62
Abstract: The present invention provides modified glucagon-like peptide 1 (GLP1) polypeptides, fusion proteins comprising modified GLP1 polypeptides, and methods of use thereof. In various embodiments of the invention, the fusion proteins are GLP1 receptor agonists that comprise a modified GLP1 fused to a stabilizing domain. In some embodiments, the fusion proteins comprising modified GLP1 are useful for treating or ameliorating a symptom or indication of a disorder such as obesity and diabetes.
